Form 4: NextCure CEO Michael Richman Granted Stock Options

NextCure CEO Michael Richman was granted employee stock options to purchase 244,400 shares of common stock on March 29, 2024.

Summary

• Michael Richman, the President and CEO of NextCure, Inc., was granted employee stock options on March 29, 2024.
• The options grant him the right to buy 244,400 shares of NextCure's common stock at an exercise price of $2.23 per share.
• The options vest fully on March 29, 2025, one year after the grant date, and expire on March 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant is relative to the size of the company and the role of the executive.
• Comparable companies such as Arcus Biosciences, Gritstone Bio, and Immatics Biotechnologies also utilize stock options as part of their executive compensation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO.
• Employees may see this as a sign of confidence in the company's future.

Key Dates